下一代糖尿病药物传输市场规模、份额和成长分析（按产品、人口统计、适应症、最终用户和地区划分）—产业预测，2025-2032年

全球下一代糖尿病药物输送市场预计在 2023 年达到 363 亿美元，从 2024 年的 393.1 亿美元增长到 2032 年的 744 亿美元，在预测期（2025-2032 年）内复合年增长率为 8.3%。

全球新一代糖尿病药物传输市场正经历显着成长，这主要得益于全球糖尿病盛行率的不断攀升。这推动了对更有效、更便利、更微创治疗方法的需求。研究重点正从单纯控制血糖值转向开发能够促进减重、改善心血管健康并最终提升患者生活品质的治疗方法，从而促进研发投入和市场扩张。然而，分析显示，该市场仍面临许多挑战，包括创新治疗方法和医疗设备的高成本，阻碍了健保报销和病患可近性。此外，冗长且成本高昂的监管核准流程，以及开发可靠的非侵入式系统和全自动「闭合迴路」管理系统的技术壁垒，也对未来的市场成长构成重大阻碍。

全球下一代糖尿病药物传输市场驱动因素

全球新一代糖尿病药物传输市场的显着扩张主要受1型和2型糖尿病盛行率持续上升的驱动。越来越多的患者需要有效的治疗措施，凸显了市场对创新便利治疗方案的巨大需求。随着确诊病例的增多，开发能够满足多样化医疗需求的先进药物输送系统变得至关重要，这进一步推动了市场成长。治疗方法方案的拓展不仅旨在改善患者预后，更致力于简化糖尿病管理，以掌握不断扩大的市场机会。

限制全球下一代糖尿病药物输送市场发展的因素

全球新一代糖尿病药物传输市场面临的主要挑战之一是这些先进治疗方法和设备的高昂成本，这往往超出了许多患者的经济承受能力。这种经济负担使得患者难以获得必要的治疗。此外，从公共和私人保险公司获得报销也存在许多障碍，这进一步限制了患者获得这些重要治疗方法的机会，尤其是在医疗资源有限的新兴市场。消除这些经济障碍对于确保创新糖尿病疗法的更广泛应用至关重要。

糖尿病治疗用下一代药物输送系统的全球市场趋势

全球下一代糖尿病药物输送市场的发展动力源于对设备间互通性和互联性日益增长的需求。患者正在寻求能够将持续血糖监测仪 (CGM) 与胰岛素帮浦整合的个人化解决方案，这催生了开放通讯协定系统的趋势。这项转变不仅增强了患者的自主性，还透过实现无缝资料交换优化了糖尿病管理。随着製造商积极响应这一主导需求，我们预计将涌现出更多创新药物传输解决方案，这些方案将优先考虑用户友好的应用程式、更便捷的数据存取以及更佳的治疗效果。这将为糖尿病护理领域创造一个更互联互通的环境。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球下一代糖尿病药物传输市场规模（按产品和复合年增长率划分）（2025-2032 年）

• 市场概览
• 吸入式胰岛素
• 口服胰岛素
• 胰岛素贴剂
• CGM系统
• 人工胰臟

全球下一代糖尿病药物输送市场按人口统计和复合年增长率划分（2025-2032 年）

• 市场概览
• 成年人口（14岁以上）
• 儿童人口（14岁以下）

全球下一代糖尿病药物传输市场按适应症和复合年增长率划分（2025-2032 年）

• 市场概览
• 1型糖尿病
• 2型糖尿病

全球下一代糖尿病药物传输市场（按最终用户和复合年增长率划分）（2025-2032 年）

• 市场概览
• 诊断/诊所
• 加护病房（ICU）
• 家庭医疗保健

全球下一代糖尿病药物传输技术市场规模及复合年增长率（2025-2032 年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2024 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2024 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2022-2024年营收年比比较

主要企业简介

• Novo Nordisk A/S（Denmark）
• Medtronic Plc（Ireland）
• Abbott Laboratories（United States）
• Dexcom, Inc.（United States）
• Eli Lilly and Company（United States）
• Sanofi（France）
• Insulet Corporation（United States）
• Tandem Diabetes Care, Inc.（United States）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• MannKind Corporation（United States）
• Becton, Dickinson and Company（BD）（United States）
• Ypsomed AG（Switzerland）
• Senseonics Holdings, Inc.（United States）
• Diabeloop SAS（France）
• Beta Bionics, Inc.（United States）
• Embecta Corp.（United States）
• Biocon Limited（India）
• Nemaura Medical Inc.（United Kingdom）
• Novartis AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）

结论与建议

Global Next Generation Diabetes Therapy Drug Delivery Market size was valued at USD 36.3 billion in 2023 and is poised to grow from USD 39.31 billion in 2024 to USD 74.4 billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).

The global market for next generation diabetes therapy and drug delivery is experiencing significant growth, primarily fueled by the rising prevalence of diabetes worldwide. There is a substantial demand for more effective, user-friendly, and minimally invasive treatment options. The focus is shifting from merely managing glucose levels to developing therapies that promote weight loss, enhance cardiovascular health, and ultimately improve patients' quality of life, leading to heightened research and development efforts and market expansion. However, the analysis reveals considerable challenges, including high costs for innovative therapies and devices, which impede reimbursement and access. Additionally, lengthy and expensive regulatory approval processes, coupled with technical hurdles in creating reliable non-invasive systems and fully automated "closed-loop" management, pose significant barriers to future growth in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Next Generation Diabetes Therapy Drug Delivery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Next Generation Diabetes Therapy Drug Delivery Market Segments Analysis

Global Next Generation Diabetes Therapy Drug Delivery Market is segmented by Product, Demographic, Indication, End User and region. Based on Product, the market is segmented into Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas. Based on Demographic, the market is segmented into Adult Population (>14years) and Child Population (14years). Based on Indication, the market is segmented into Type 1 Diabetes and Type 2 Diabetes. Based on End User, the market is segmented into Diagnostic/Clinics, ICUs and Home Healthcare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Next Generation Diabetes Therapy Drug Delivery Market

The remarkable expansion of the global next generation diabetes therapy drug delivery market is primarily driven by the continuous increase in the prevalence of Type 1 and Type 2 diabetes. This growing population of individuals requiring effective management options highlights a significant demand for innovative and convenient therapeutic solutions. As more people are diagnosed, the need for advanced drug delivery systems that cater to their diverse healthcare needs becomes critical, further fueling the market's growth. Enhanced treatment alternatives not only aim to improve patient outcomes but also strive to simplify the management of diabetes, thereby addressing an ever-expanding market opportunity.

Restraints in the Global Next Generation Diabetes Therapy Drug Delivery Market

One of the significant challenges facing the Global Next Generation Diabetes Therapy Drug Delivery market is the high cost associated with these advanced therapies and devices, which often surpasses the financial capabilities of many patients. This economic burden makes it difficult for individuals to afford necessary treatments. Additionally, obtaining reimbursement from both public and private insurers poses a substantial hurdle, further limiting patient access to these crucial therapies, particularly in emerging markets where healthcare resources may be more constrained. Addressing these financial barriers is essential to ensuring broader accessibility and adoption of innovative diabetes treatments.

Market Trends of the Global Next Generation Diabetes Therapy Drug Delivery Market

The global next generation diabetes therapy drug delivery market is increasingly driven by the demand for interoperability and connectivity among devices. Patients are seeking personalized solutions that enable them to integrate their continuous glucose monitors (CGMs) with insulin pumps, fostering a trend towards open-protocol systems. This shift is not only enhancing patient autonomy but also optimizing diabetes management by facilitating seamless data exchange. As manufacturers respond to this consumer-driven demand, we can anticipate innovative drug delivery systems that prioritize user-friendly applications, increased data accessibility, and improved therapeutic outcomes, ultimately shaping a more interconnected landscape in diabetes care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Product & CAGR (2025-2032)

• Market Overview
• Inhalable Insulin
• Oral Insulin
• Insulin Patches
• CGM Systems
• Artificial Pancreas

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Demographic & CAGR (2025-2032)

• Market Overview
• Adult Population (>14years)
• Child Population (14years)

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Type 1 Diabetes
• Type 2 Diabetes

Global Next Generation Diabetes Therapy Drug Delivery Market Size by End User & CAGR (2025-2032)

• Market Overview
• Diagnostic/Clinics
• ICUs
• Home Healthcare

Global Next Generation Diabetes Therapy Drug Delivery Market Size & CAGR (2025-2032)

• North America (Product, Demographic, Indication, End User)
  • US
  • Canada
• Europe (Product, Demographic, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Demographic, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Demographic, Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Demographic, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tandem Diabetes Care, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MannKind Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Senseonics Holdings, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diabeloop SAS (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beta Bionics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Embecta Corp. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nemaura Medical Inc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations